PROCESS FOR THE PRODUCTION OF FORSKOLIN DERIVATIVES BY MICROBIAL TRANSFORMATIONS

1. A process for the preparation of forskolin derivatives, which comprises a particular microorganism being allowed to act on a particular forskolin derivative as substrate in a nutrient medium in a customary manner and, after completion of the fermentation, the compound which has formed being isola...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KHANDELWAL, YATENDRA, RUPP, RICHARD HELMUT, INAMDAR, PRABHAKAR KRISHNAJI, DE SOUZA, NOEL JOHN, GANGULI, BIMAL NARESH, NADKARNI, SURESH RUDRA, CHATTERJEE, SUKUMAR, DOHADWALLA, ALIHUSSEIN N
Format:	Patent
Sprache:	eng ; ger
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES USING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	1. A process for the preparation of forskolin derivatives, which comprises a particular microorganism being allowed to act on a particular forskolin derivative as substrate in a nutrient medium in a customary manner and, after completion of the fermentation, the compound which has formed being isolated from the culture broth and the mycelium by extraction with an organic solvent and subsequent chromatography and/or crystallization, where a) with the compound of the formula III see diagramm : EP0189801,P16,F1 as substrate and using the strain H/134 (DSM 3205), there is obtained the compound of the formula IV see diagramm : EP0189801,P16,F2 b) with the compound of the formula IV as substrate and using the strain FF/406 (DSM 3211), there is obtained the compound of the formula V see diagramm : EP0189801,P16,F3 in which Ac denotes the radical CH3 CO-, c) with the compound of the formula VI see diagramm : EP0189801,P16,F4 in which Ac denotes the radical CH3 CO-, as substrate and c1 ) using the strain FF/172 (DSM 3208), there is obtained the compound of the formula VII see diagramm : EP0189801,P17,F5 or c2 ) using the strain FF/101 (DSM 3207), there is obtained the compound of the formula VIII see diagramm : EP0189801,P17,F6 in which Ac denotes the radical CH3 CO-, or c3 ) using the strain H/134 (DSM 3205), there is obtained the compound of the formula IX see diagramm : EP0189801,P17,F7 or c4 ) using the strain FF/101 (DSM 3207), there is obtained the compound of the formula X see diagramm : EP0189801,P17,F8 in which Ac denotes the radical CH3 CO-, or c5 ) using the strain H/134 (DSM 3205), there is obtained the compound of the formula XI see diagramm : EP0189801,P18,F9 in which Ac denotes the radical CH3 CO-, or c6 ) using the strain FF/173 (DSM 329) or H/1 (DSM 3202), there is obtained the compound of the formula XII see diagramm : EP0189801,P18,F10 in which Ac denotes the radical CH3 CO-, or c7 ) using the strain FF/383 (DSM 3210), there is obtained the compound of the formula XIII see diagramm : EP0189801,P18,F11 or C8 ) using the strain FF/695 (DSM 3212), there is obtained the compound of the formula XIV see diagramm : EP0189801,P18,F12 in which Ac denotes the radial CH3 CO-, or c9 ) using the strain FF/93 (DSM 3206) or FF/172 (DSM 3208), there is obtained the compound of the formula XV see diagramm : EP0189801,P19,F13 or c10 ) using the strain H/3 (DSM 3203) or H/19 (DSM 3204) or Y-82 52 904 (DSM 3213), there is obtained the compound of the formula XVI see